Challenging arterial calcification disease associated with rare *NT5E* gene mutation

Giampiero Avruscio,¹ Mauro Massucci ,² Angelo Adamo ,¹ Alfredo Brusco ,^{3,4}

¹Department of Cardiac, Thoracic and Vascular Sciences, Angiology Unit, University of Padua, Padova, Italy

²Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy

³Department of Medical Sciences, University of Turin, Torino, Italy

⁴Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Torino, Italy

Correspondence to
Professor Alfredo Brusco;
alfredo.brusco@unito.it

Accepted 22 May 2020

DESCRIPTION

A 47-year-old woman has been suffering from intermittent claudication since she was 33 years old. The symptoms have slowly worsened during the following years and the patient was unable to walk more than 200 m without leg pain (Leriche-Fontain IIb) at admission. She had a history of hydroxyapatite crystal calcification disease diagnosed at the age of 19 years, after the onset of bilateral symmetric hand arthritis and Raynaud phenomenon.

On physical examination, peripheral pulses were weak at palpation and ankle-brachial index (ABI) measurement was markedly decreased (0.59 on the right and 0.38 on the left leg). Echocolor Doppler ultrasounds of the lower limbs documented severely calcified arteries (figure 1A,B), while no calcification of the carotid walls was found. The patient underwent coronary CT scan, abdominal and thoracic aorta CT scan and lower limbs artery CT scan and X-ray to accurately assess the systemic calcium deposit and to determine the global cardiovascular risk. The images revealed severe calcific arterial disease limited to femoral and popliteal arteries bilaterally with developed collateral neovascularisation (figure 1C,D); coronary arteries and the whole

Figure 2 Family pedigree and electropherograms of the pathogenic *NT5E* gene variant in exon 9.

aorta were free from vascular wall calcification. Hands X-ray displayed pericapsular calcification of the finger joints. A wide panel of laboratory examination, including serum calcium and phosphate, vitamin-D, parathyroid hormone, antinuclear antibodies, antiextractable nuclear antigen antibodies were unremarkable.

We performed Sanger sequencing of the coding exons of the *NT5E* gene (table 1) and identified the homozygous c.1608dupA–p.Val537SerfsTer7 variant, consistent with the diagnosis of ‘arterial calcification due to deficiency of CD73’ also known as ‘calcification of joints and arteries’ (CALJA) syndrome (MIM211800). The variant is predicted loss-of-function, described in another case with the disease¹ and reported in ClinVar database (VCV000029689.1). Segregation analysis showed both parents were heterozygotes (figure 2).

Arterial calcification due to deficiency of CD73 is a rare syndrome defined by arterial calcification that targets vessels below the diaphragm, notably the large lower extremity arteries, and spares coronary circulation. Mutations in *NT5E* gene, encoding for the plasma membrane enzyme CD73 which hydrolyses adenosine monophosphate (AMP) to adenosine and inorganic phosphate (Pi), were identified in adults from three different families affected with the disease.¹ From this first description, only four other families have been described worldwide.^{2–5}

In vitro assays demonstrated that CD73-deficient fibroblasts reduced extracellular adenosine levels and enhanced the activity of tissue non-specific alkaline phosphatase, which generates procalcifying extracellular Pi. CALJA is an adult-onset disease, with the first symptoms occurring during the second decade of life.

Figure 1 Imaging panel showing wide calcification of the common femoral artery with signs of partial demodulated blood flow on echocolor Doppler scan (A) with distal evidence of poststenotic flow (B); X-ray (C) and CT scan (D) of both legs displaying the typical pattern of massive arterial calcification with several collateral vessels.

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Avruscio G, Massucci M, Adamo A, et al. *BMJ Case Rep* 2020;**13**:e235365. doi:10.1136/bcr-2020-235365

Images in...

Table 1 PCR primers used for Sanger sequencing of *NT5E* gene

NT5E-1F	5'-cctagctgctcgccctactc
NT5E-1R	5'-actctgcatcgctgtctttc
NT5E-2F	5'-tgtctcatagacttagctgtttga
NT5E-2R	5'-ataatgccaagctgtgattaggc
NT5E-3F	5'-ttaaggtgttaacctttgcatga
NT5E-3R	5'-agttacaaagcaaaagacacag
NT5E-4F	5'-agcatgtatgtacaagggtgac
NT5E-4R	5'-ggagcaaaatccagccatctaa
NT5E-5F	5'-ccagaatttagccagtgtagat
NT5E-5R	5'-tcgcatccttctctctctcc
NT5E-6F	5'-gactcgaaggaagagccaga
NT5E-6R	5'-ggcagaaccataacagaaagga
NT5E-7F	5'-attttcgaagctattttctctc
NT5E-7R	5'-aggaaatgccatgagactgtgga
NT5E-8F	5'-gaatctcccttggatctggtg
NT5E-8R	5'-cttgcccaattttgtgtctt
NT5E-9F	5'-acaaggactactctactgttgatga
NT5E-9R	5'-agcctgtaaagatggtttgtgct

PCR conditions were identical for all amplimers. PCR was performed using the KAPA DNA PCR kit (Roche Diagnostics, Risch-Rotkreuz, Switzerland) under the specified conditions and 50 ng of genomic DNA. We performed a touch-down PCR using the following protocol: 95°C 3 min; 14 cycles 95°C 15 s, 63°C 15 s, 72°C 3 s; 29 cycles 95°C 15 s, 63°C–0.5°C/cycle 15 s, 72°C 3 s. Final extension 72°C 1 min. PCR products were purified using ExoSAP, cycle sequenced and run on a 3130XL ABI Prism apparatus (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, USA).

Learning points

- ▶ Arterial calcification due to deficiency of CD73 is a rare genetic syndrome secondary to *NT5E* gene mutation characterised by arterial calcification which selectively targets vessels below the diaphragm together with periarticular calcification.
- ▶ A complete imaging evaluation with duplex ultrasounds, CT scan and X-ray is of utmost importance to identify the typical arterial and articular calcification pattern.
- ▶ Arterial calcification due to deficiency of CD73 treatment is still a challenge with bisphosphonates as the only pharmacological therapy under evaluation by clinical trials.

The pathogenetic calcification progresses for years, possibly leading to neoangiogenic vascular remodelling and development of small collateral vessels. This fact could explain the marked decrease of ABI index with a mild functional impairment of our patient.

An approved therapy for patients affected by arterial calcification due to deficiency of CD73 has not yet been available, however, an ongoing clinical trial is testing the effectiveness and the safety of etidronate as a standard treatment for this syndrome.

Acknowledgements We would like to thank the patient for participating in this study.

Contributors GA, MM and AA performed and interpreted clinical evaluation and drafted the manuscript. AB performed and interpreted genetic analyses. All authors revised the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iDs

Mauro Massucci <http://orcid.org/0000-0003-0895-440X>

Angelo Adamo <http://orcid.org/0000-0001-7668-8938>

Alfredo Brusco <http://orcid.org/0000-0002-8318-7231>

REFERENCES

- 1 St Hilaire C, Ziegler SG, Markello TC, *et al*. NT5E mutations and arterial calcifications. *N Engl J Med* 2011;364:432–42.
- 2 Ichikawa N, Taniguchi A, Kaneko H, *et al*. Arterial calcification due to deficiency of CD73 (ACDC) as one of rheumatic diseases associated with Periarticular calcification. *J Clin Rheumatol* 2015;21:216–20.
- 3 Zhang Z, He J-W, Fu W-Z, *et al*. Calcification of joints and arteries: second report with novel NT5E mutations and expansion of the phenotype. *J Hum Genet* 2015;60:561–4.
- 4 de Nijs T, Albuissin J, Ockeloen CW, *et al*. Isolated arterial calcifications of the lower extremities: a clue for NT5E mutation. *Int J Cardiol* 2016;212:248–50.
- 5 Yoshioka K, Kuroda S, Takahashi K, *et al*. Calcification of joints and arteries with novel NT5E mutations with involvement of upper extremity arteries. *Vasc Med* 2017;22:541–3.

Copyright 2020 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow